Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Published online first on March 28, 2008
[Molecular Cancer Therapeutics, 10.1158/1535-7163.MCT-07-0579]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
1535-7163.MCT-07-0579v1
7/4/788    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Miselis, N. R.
Right arrow Articles by Kane, A. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miselis, N. R.
Right arrow Articles by Kane, A. B.

Research Articles: Therapeutics, Targets, and Development

Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma

Nathan R. Miselis 1*, Zhijin J. Wu , Nico Van Rooijen , Agnes B. Kane

1 1Department of Pathology and Laboratory Medicine and 2Center for Statistical Sciences, Brown University, Providence, Rhode Island and 3Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands

* To whom correspondence should be addressed. E-mail: Nathan_Miselis{at}brown.edu.


   Abstract

Tumors are a mixture of neoplastic and host stromal cells, which establish a microenvironment that contributes to tumor progression. In this study, the contribution of tumor-associated macrophages (TAMs) to tumor growth and metastasis was examined using an orthotopic, immunocompetent murine model of diffuse malignant peritoneal mesothelioma. The expression profile of cytokines and chemokines in solid tumors was consistent with a M2-polarized, TAM-mediated immunosuppressive microenvironment. TAMs were targeted using liposome-encapsulated clodronate (CLIP). Exposure of tumor spheroids to CM-DiI-labeled CLIP in situ confirms targeting of macrophages and not mesothelioma cells. Intraperitoneal (i.p.) delivery of CLIP produced apoptosis in tumor spheroids and solid tumors in contrast to delivery of liposome-encapsulated PBS or PBS. Mice received an i.p. injection of mesothelioma cells with CLIP delivered i.p. every 5 days. This treatment protocol produces a 4-fold reduction in the number of tumors, a 17-fold reduction in the relative tumor burden, and a 5-fold reduction in invasion and metastasis when compared with mice exposed to liposome-encapsulated PBS or PBS. Following transplantation of tumor spheroids and treatment with CLIP, mice showed a 4-fold reduction in the number of tumors and a 15-fold reduction in relative tumor burden. Mice bearing established tumors showed a 2-fold reduction in the number of tumors and relative tumor burden when exposed to half the previous dose of CLIP delivered by repeated i.p. injection. These reductions in tumor burden are statistically significant and identify TAMs as an important host-derived cell that contributes to growth, invasion, and metastasis in diffuse malignant peritoneal mesothelioma. [Mol Cancer Ther 2008;7(4):788–99]

Key Words: Bisphosphonates, Macrophages, Mesothelioma, Orthotopic model, Metastasis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.